Journal
CANCER INVESTIGATION
Volume 28, Issue 3, Pages 259-267Publisher
TAYLOR & FRANCIS INC
DOI: 10.3109/07357900802112719
Keywords
Rectal cancer; sphincter preservation; neoadjuvant treatment
Categories
Ask authors/readers for more resources
Current treatment of mid and lower rectal cancer includes neoadjuvant therapy, such as radiotherapy or radiochemotherapy. Randomized trials have demonstrated that neoadjuvant therapy improves local control. However, with the exception of one study, it does not improve overall and cancer-specific survival. In addition, the role of neoadjuvant therapy in enhancing the surgeon's ability to perform sphincter-saving surgery is still controversial. We provide an overview of reported randomized trials using neoadjuvant therapy in patients with rectal cancer. We have examined the most significant factors influencing sphincter preservation and the manner in which these factors are affected by neoadjuvant treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available